Venous Thromboembolism Clinical Trial
Official title:
Prospective Randomized Evaluation of the Denali and Option Inferior Vena Cava Filters
This research study is a prospective randomized trial evaluating the relative safety of two
inferior vena cava (IVC) filters used to prevent the migration of potentially dangerous
deadly blood clots from the legs to the lung in patients who cannot take blood thinners. All
eligible patients will have been ordered to have a IVC filter placed by their primary medical
team and filters will be placed in these patients whether or not they wish to participate in
this trial as part of standard of care. The investigators will follow up with patients 30
days after IVC filter placement and ask them to come back for filter removal if medically
appropriate. If removal is not medically appropriate in 30 days, the investigators will
attempt to schedule removal every 30 days after initial placement.
Primary outcome measures will be IVC filter complications such as filter penetration through
the IVC wall and into other organs, filter tilt, filter migration, filter fracture and clots
formed within the filter. All of these are reported complications of all IVC filters.
The research also aims to improve the standard of care for IVC filter patient follow up as
the FDA and Society of Interventional Radiology recommend that IVC filters be removed as soon
as it is safe to do so.
Hypothesis:
The investigators hypothesize that there is no significant difference in efficacy and
complication rate between the Option and the Denali filter.
This is a prospective, randomized trial comparing two FDA-approved inferior vena cava
filters, the Denali retrievable IVC filter (Bard Peripheral Vascular Inc., Tempe, AZ) and the
Option Elite (Argon Medical, Athens, Texas).
Patients scheduled for IVC filter placement at UCSF Department of Interventional Radiology
(IR) will be asked by the IR physician performing the procedure at either UCSF Mt. Zion or
Moffitt hospital if they wish to participate in this prospective, randomized study.
Recruitment will be conducted by the physicians performing the IR procedures only. No
additional recruitment calls, emails, posters or web pages are necessary. All procedures and
the randomization to one of the two experimental groups will be carefully explained before
obtaining signed written consent.
Screening:
Screening will be conducted by the IR physician prior to the placement of the IVC filters.
Since this is a standard of care study, patients who are recommended for IVC filter placement
and are scheduled for the procedure are generally eligible.
The screening procedures are part of routine care before IVC filter placement and would be
done even if patients did not join the study.
The study doctor will review the results of most recent routine care imaging scans (CT or
MRI) of the abdomen and pelvis. This is done to confirm that the diameter of IVC is no wider
than 2.8cm. Both filters are FDA-approved to be placed in an IVC with maximal diameter of
2.8cm.
The study doctor will also review ultrasound of the lower extremity, when available, to
confirm that a blood clot was in fact present prior to performing the study. This ensures
that patients who present for IVC filter placement are screened properly.
The following screening procedures should be done within 12 days before the IVC filter
placement procedure as part of the standard of care.
- A complete physical exam
- The study doctor will ask about medical history and how well patient is able to do daily
activities
- Routine care blood tests (about 2 tablespoons) o This is to ensure that the INR and
platelet count of the patient is within the safe limits to perform an invasive
procedure.
After Enrollment:
If the screening procedures show that the patient is eligible and consents to take part in
the study, IVC filter placement will occur after randomization.
After enrollment, the following procedures will be done during the study: Just as with
screening, all of these procedures are part of regular IVC filter placement care.
Randomization:
Randomization will occur on the day of procedure or prior clinic visit with IR physician to
either the Denali or Option IVC filter. All IR attending physicians on the protocol are
familiar with placement of either filter type. Prior to opening study to accrual, 75 sealed
security envelopes with the word Denali printed on a card inside and 75 sealed security
envelopes with the word Option will be assembled by IR staff not involved in the research.
The envelopes will be mixed up and placed in a bag. Computerized randomization programs and
tables were considered but we feel the envelopes will work best as there may be limited time
after patient is consented and procedure begins. This is especially true as some filters are
placed emergently. Previous IR studies have used this randomization technique with great
success.
Filter Placement:
Placement of an IVC filter involves the insertion of a plastic tube (catheter) into a vein in
the neck. Some numbing medicine (Lidocaine) will be injected in the skin over the vein before
the catheter is inserted. Intravenous medications will be given to induce moderate sedation
(Fentanyl for analgesic and Versed for moderate sedation). Once the catheter has been placed
into the vein, it will be advanced into the IVC. Once in correct position, x-ray contrast
material (x-ray dye-Omnipaque 350) will be injected through the catheter and x-ray pictures
taken. A series of x-ray pictures will be obtained of the IVC. These pictures are taken as
part of standard of care to determine the position of the renal veins with respect to the
IVC. The top of the filter must sit below the renal veins so it does not cause obstruction of
the renal veins. In addition, pictures of the IVC are taken to serve as another tool in
measuring the diameter of the IVC to make sure the diameter of the IVC is less than 2.8cm.
This is particularly important in situations when a CT or MRI of the abdomen and pelvis is
not available to have reviewed prior to the procedure. Once pictures are obtained and it is
made certain that the IVC diameter is less than 2.8cm, the filter will be inserted through
the catheter, and placed below the renal veins. During the placement procedure, positioning
of the filter will be monitored with x-ray pictures. At the completion of the procedure the
catheter will be removed and pressure will be applied to the insertion site until the
bleeding has stopped. All of this is part of routine standard of care for placement of the
filter. The doctor performing the procedure will be asked to complete a short questionnaire
after IVC filter placement which will be attached to "Study Documents".
Follow-Up:
After the IVC filter placement procedure patient status will be followed by the
interventional radiology doctors.
Per standard of care after IVC filter placement, patient will be monitored in the hospital
for up to 1 hour after the procedure. If patient is in stable condition and sedation has
resolved, they will return home the same day or returned to their hospital rooms.
A tentative appointment for follow up and filter retrieval will be ordered by IR physician at
time of filter placement in APEX. This will ensure that scheduling and study staff will be
aware that further patient and primary care follow-up is required.
Patient primary care physician and/or relevant medical staff will be telephoned one month
after IVC filter placement to determine if patient is medically stable and suitable for IVC
filter removal.
If IR and other doctors agree that IVC filter removal is recommended, patient will be
scheduled to return for follow-up imaging and filter retrieval. If patient is not medically
stable or still at high risk for blood clots, we will attempt to schedule a follow up one
month later. Close contact with primary physician and patient will be maintained to ensure
that filter is removed as soon as possible. APEX scheduling will be used to make sure follow
up is performed at regular intervals.
At follow-up appointment these routine tests per standard of care before IVC filter removal
will be performed:
- A physical exam
- The study doctor will ask about medical history, how well patient is able to do daily
activities, and if they are experiencing any possible symptoms related to the IVC filter
placement such as abdominal or back pain.
- A rotation CT focused to the site of the filter will be performed as part of routine
practice of filter removal. This is done to ensure the filter has not migrated or that
the filter has not penetrated through the walls of the IVC such that filter retrieval
would be unsafe.
- IR physician will determine if patient status is stable and safe for IVC filter removal.
If not, physician will discuss with primary care doctor if filter needs to remain
permanently in patient or if later retrieval should be considered at subsequent follow
up visits.
- IVC filter retrieval will be performed under moderate sedation. This procedure is very
similar in nature to the filter placement procedure. The IVC filter is removed via a
similar process to the way in which it was placed. X-ray dye (contrast) will be injected
around the filter to assure that the filter and the area beneath the filter are free of
blood clots and that it is safe to proceed with removal. A catheter-based snare will be
used to engage the hook at the end of the filter and the filter will then be enveloped
by a removal sheath and removed from the body.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05347550 -
Examining the Benefit of Graduated Compression Stockings in the Prevention of vEnous Thromboembolism in Low-risk Surgical Patients
|
N/A | |
Enrolling by invitation |
NCT05794165 -
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism
|
Phase 2 | |
Completed |
NCT02379806 -
The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study
|
Phase 3 | |
Recruiting |
NCT03691753 -
Safety and Efficacy Study of Fitaya Vena Cava Filter
|
N/A | |
Completed |
NCT02197416 -
Safety of Dabigatran Etexilate in Blood Clot Prevention in Children
|
Phase 3 | |
Recruiting |
NCT05378035 -
DOAC in Chinese Patients With Atrial Fibrillation
|
||
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT01895777 -
Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)
|
Phase 3 | |
Completed |
NCT05897697 -
Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
|
||
Completed |
NCT04736420 -
Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT04735523 -
Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT04736719 -
Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT02829957 -
RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
|
Phase 2/Phase 3 | |
Completed |
NCT02746185 -
Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban
|
Phase 3 | |
Completed |
NCT02912234 -
Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants
|
Phase 1 | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT02661568 -
Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES)
|
N/A | |
Completed |
NCT02223260 -
Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age
|
Phase 2 | |
Completed |
NCT01431456 -
Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
|
Phase 3 | |
Completed |
NCT01976988 -
Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery
|
Phase 3 |